{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:35:01Z","timestamp":1793936101042,"version":"4.8.0"},"reference-count":146,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic HBV infection is a global public health burden estimated to impact nearly 300 million persons worldwide. Despite the advent of potent antiviral agents that effectively suppress viral replication, HBV cure remains difficult to achieve because of the persistence of covalently closed circular DNA (cccDNA), HBV\u2010DNA integration into the host genome, and impaired immune response. Indefinite treatment is necessary for most patients to maintain level of viral suppression. The success of direct\u2010acting antivirals (DAAs) for hepatitis C treatment has rejuvenated the search for a cure for chronic hepatitis B (CHB), though an HBV cure likely requires an additional layer: immunomodulators for restoration of robust immune responses. DAAs such as entry inhibitors, capsid assembly modulators, inhibitors of subviral particle release, cccDNA silencers, and RNA interference molecules have reached clinical development. Immunomodulators, namely innate immunomodulators (Toll\u2010like receptor agonists), therapeutic vaccines, checkpoint inhibitors, and monoclonal antibodies, are also progressing toward clinical development. The future of the HBV cure possibly lies in triple combination therapies with concerted action on replication inhibition, antigen reduction, and immune stimulation. Many obstacles remain, such as overcoming translational failures, choosing the right endpoint using the right biomarkers, and leveraging current treatments in combination regimens to enhance response rates. This review gives an overview of the current therapies for CHB, HBV biomarkers used to evaluate treatment response, and development of DAAs and immune\u2010targeting drugs and discusses the limitations and unanswered questions on the journey to an HBV cure.<\/jats:p>","DOI":"10.1002\/hep.32314","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T08:43:42Z","timestamp":1641458622000},"page":"233-250","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":154,"title":["Getting to HBV cure: The promising paths forward"],"prefix":"10.1097","volume":"76","author":[{"given":"Scott","family":"Fung","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease,Toronto General Hospital,Toronto,Ontario,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-4610","authenticated-orcid":false,"given":"Hannah S. J.","family":"Choi","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease,Toronto General Hospital,Toronto,Ontario,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-5840","authenticated-orcid":false,"given":"Adam","family":"Gehring","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease,Toronto General Hospital,Toronto,Ontario,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease,Toronto General Hospital,Toronto,Ontario,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"hep32314-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL\u2010AASLD HBV Treatment Endpoints Conference","volume":"72","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long\u2010term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta\u2010analysis","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32314-bib-0004-20250824","article-title":"Rnai\u2010based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis b virus DNA is a source of hbsag","volume":"9","year":"2017","journal-title":"Sci Transl Med"},{"key":"hep32314-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep32314-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep32314-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)\u2010infection: a European perspective","volume":"52","year":"2010","journal-title":"J Hepatol"},{"key":"hep32314-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta\u2010analyses","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"hep32314-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community\u2010based follow\u2010up study","volume":"139","year":"2010","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/apt.13170","article-title":"Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection","volume":"41","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32314-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta\u2010analysis","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2021.04.040","article-title":"The times they are a\u2010changing\u2014a refined proposal for finite HBV nucleos(t)ide analogue therapy","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"hep32314-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response\u2010guided peginterferon therapy in hepatitis B e antigen\u2010positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep32314-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core\u2010related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"hep32314-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core\u2010related antigen in the natural history of chronic hepatitis B","volume":"20","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"hep32314-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High level of hepatitis B core\u2010related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load","volume":"157","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/cid\/ciaa1015","article-title":"Circulating pregenomic hepatitis B virus RNA is primarily full\u2010length in chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy","volume":"72","year":"2021","journal-title":"Clin Infect Dis"},{"key":"hep32314-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV\u2010RNA levels and intrahepatic viral as well as histologic activity markers in entecavir\u2010treated patients","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep32314-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV\u2010RNA in chronic HBV infection","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"hep32314-bib-0021-20250824","article-title":"Single hepatocytes show persistence and transcriptional inactivity of hepatitis B","volume":"5","year":"2020","journal-title":"JCI Insight"},{"key":"hep32314-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","year":"2021","journal-title":"Gut"},{"key":"hep32314-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg\u2010negative chronic hepatitis B patients","volume":"74","year":"2021","journal-title":"J Hepatol"},{"key":"hep32314-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core\u2010related antigen predict outcomes in hepatitis B e antigen\u2010negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep32314-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciaa013","article-title":"Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg\u2010negative chronic hepatitis B","volume":"72","year":"2021","journal-title":"Clin Infect Dis"},{"key":"hep32314-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.13440","article-title":"Entecavir safety and effectiveness in a national cohort of treatment\u2010na\u00efve chronic hepatitis B patients in the US\u2014the ENUMERATE study","volume":"43","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32314-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep32314-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12072-019-09943-6","article-title":"Long\u2010term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5\u2010year results","volume":"13","year":"2019","journal-title":"Hepatol Int"},{"key":"hep32314-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg\u2010positive chronic hepatitis B","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3748\/wjg.v13.i31.4264","article-title":"A one\u2010year trial of entecavir treatment in patients with HBeAg\u2010positive chronic hepatitis B","volume":"13","year":"2007","journal-title":"World J Gastroenterol"},{"key":"hep32314-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"348","year":"2003","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","article-title":"Four years of lamivudine treatment in Chinese patients with chronic hepatitis B","volume":"19","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"hep32314-bib-0035-20250824","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1478-3231.2011.02641.x","article-title":"Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg\u2010positive chronic hepatitis B","volume":"32","year":"2012","journal-title":"Liver Int"},{"key":"hep32314-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment","volume":"29","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"hep32314-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long\u2010term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","year":"2011","journal-title":"J Infect Dis"},{"key":"hep32314-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep32314-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian\u2010Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"hep32314-bib-0040-20250824","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus\u2010specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg\u2010negative chronic hepatitis B","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep32314-bib-0041-20250824","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus\u2013specific T cells associate with viral control upon nucleos(t)ide\u2010analogue therapy discontinuation","volume":"128","year":"2018","journal-title":"J Clin Invest"},{"key":"hep32314-bib-0042-20250824","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg\u2010negative patients with chronic hepatitis B who stop long\u2010term treatment with adefovir","volume":"143","year":"2012","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0043-20250824","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long\u2010term response after stopping tenofovir disoproxil fumarate in non\u2010cirrhotic HBeAg\u2010negative patients\u2014FINITE study","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep32314-bib-0044-20250824","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0168-8278(20)30755-8","article-title":"Response to discontinuation of long\u2010term nucleos(t)ide analogue treatment in HBeAg negative patients: results of the Stop\u2010NUC trial","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0045-20250824","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","year":"2019","journal-title":"Gut"},{"key":"hep32314-bib-0046-20250824","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen\u2010negative chronic hepatitis B","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep32314-bib-0047-20250824","first-page":"19A","article-title":"HBsAg loss is higher among Caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multi\u2010ethnic cohort of patients with chronic hepatitis B (RETRACT\u2010B STUDY)","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep32314-bib-0048-20250824","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.14560","article-title":"Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes","volume":"47","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32314-bib-0049-20250824","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long\u2010term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"hep32314-bib-0050-20250824","first-page":"2682","article-title":"Peginterferon Alfa\u20102a, lamivudine, and the combination for HBeAg\u2010positive chronic hepatitis B","volume":"30","year":"2005","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0051-20250824","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa\u20102b alone or in combination with lamivudine for HBeAg\u2010positive chronic hepatitis B: a randomised trial","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"hep32314-bib-0052-20250824","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon Alfa\u20102a alone, lamivudine alone, and the two in combination in patients with HBeAg\u2010negative chronic hepatitis B","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0053-20250824","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra\u2010long\u2010term follow\u2010up of interferon alfa treatment for HBeAg\u2010positive chronic hepatitis B virus infection","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32314-bib-0054-20250824","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1\u20102a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0055-20250824","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/infdis\/jix024","article-title":"Pegylated interferon Alfa\u20102b add\u2010on treatment in hepatitis b virus envelope antigen\u2010positive chronic hepatitis B patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON)","volume":"215","year":"2017","journal-title":"J Infect Dis"},{"key":"hep32314-bib-0056-20250824","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","article-title":"Effect on HBs antigen clearance of addition of pegylated interferon alfa\u20102a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen\u2010negative chronic hepatitis B and sustained undetectable plasma hepatitis","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32314-bib-0057-20250824","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen\u2010positive chronic hepatitis B to peginterferon\u2010alfa","volume":"137","year":"2009","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0058-20250824","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0059-20250824","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2019.07.003","article-title":"Excellent safety and effectiveness of high\u2010dose myrcludex\u2010B monotherapy administered for 48 weeks in HDV\u2010related compensated cirrhosis: a case report of 3 patients","volume":"71","year":"2019","journal-title":"J Hepatol"},{"key":"hep32314-bib-0060-20250824","first-page":"e00835","article-title":"Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"hep32314-bib-0061-20250824","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","article-title":"The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non\u2010nucleoside inhibitors of HBV replication","volume":"92","year":"2011","journal-title":"Antiviral Res"},{"key":"hep32314-bib-0062-20250824","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.06.016","article-title":"Antiviral profiling of the capsid assembly modulator BAY41\u20104109 on full\u2010length HBV genotype A\u2010H clinical isolates and core site\u2010directed mutants in vitro","volume":"144","year":"2017","journal-title":"Antiviral Res"},{"key":"hep32314-bib-0063-20250824","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0168-8278(20)30649-8","article-title":"Antiviral activity and safety of the hepatitis B core inhibitor ABI\u2010 H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg\u2010negative chronic hepatitis B infection","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0064-20250824","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/S0168-8278(20)30790-X","article-title":"Antiviral activity and safety of the hepatitis B core inhibitor ABI\u2010 H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg\u2010positive chronic hepatitis B infection in a long\u2010term extension study","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0065-20250824","first-page":"S736","article-title":"Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"hep32314-bib-0066-20250824","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG\u2010I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","year":"2015","journal-title":"Immunity"},{"key":"hep32314-bib-0067-20250824","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0168-8278(20)30766-2","article-title":"Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0068-20250824","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa\u20102a for treatment\u2010naive patients with chronic hepatitis B virus and hepatitis D virus co\u2010infection (REP 301 and REP 301\u2010LTF): a non\u2010randomised, open\u2010label, phase 2 trial","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32314-bib-0069-20250824","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa\u20102a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0070-20250824","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2020.06.097","article-title":"Nucleic acid polymer therapy for hepatitis B virus: strong hepatitis B surface antigen decline but many unanswered questions","volume":"160","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl.","key":"hep32314-bib-0071-20250824","first-page":"S741","article-title":"Safety, tolerability and pharmacokinetics (PK) of single and multiple doses of ALG\u2010010133, an S\u2010antigen transport inhibiting oligonucleotide polymer (STOPS) for the treatment of chronic hepatitis B [Abstract]","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"hep32314-bib-0072-20250824","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1021\/jm049481d","article-title":"Design and synthesis of novel N\u2010acetylgalactosamine\u2010terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor","volume":"47","year":"2004","journal-title":"J Med Chem"},{"key":"hep32314-bib-0073-20250824","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"hep32314-bib-0074-20250824","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(20)30647-4","article-title":"Preliminary safety and antiviral activity of VIR\u20102218, an X\u2010targeting HBV RNAi therapeutic, in chronic hepatitis B patients","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0075-20250824","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(20)30597-3","article-title":"Short\u2010term treatment with RNA interference therapy, JNJ\u20103989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32314-bib-0076-20250824","first-page":"LO9","article-title":"HBV RNAi inhibitor RG6346 in phase 1b\u20132a trial was safe, well\u2010tolerated, and resulted in substantial and durable reductions in serum HBsAg levels","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep32314-bib-0077-20250824","article-title":"Efficacy and safety of the siRNA JNJ\u20103989 and\/or the capsid assembly modulator JNJ\u20106379 for the treatment of chronic hepatitis B virus infection: results from the phase 2b REEF\u20101 study","journal-title":"Hepatology"},{"issue":"Suppl.","key":"hep32314-bib-0078-20250824","first-page":"63A","article-title":"Preliminary results from a phase 2 study evaluating VIR\u20102218 alone and in combination with pegylated interferon alfa\u20102a in participants with chronic hepatitis B infection","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"hep32314-bib-0079-20250824","doi-asserted-by":"crossref","first-page":"1725\u2013","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"hep32314-bib-0080-20250824","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/v13081463","article-title":"Mechanism of hepatitis b virus cccDNA formation","volume":"13","year":"2021","journal-title":"Viruses"},{"key":"hep32314-bib-0081-20250824","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc\u2010finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","year":"2010","journal-title":"Mol Ther"},{"key":"hep32314-bib-0082-20250824","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9\u2010mediated non\u2010cleavage base editing","volume":"20","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"hep32314-bib-0083-20250824","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1172\/JCI110860","article-title":"Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers","volume":"71","year":"1983","journal-title":"J Clin Invest"},{"key":"hep32314-bib-0084-20250824","first-page":"259","article-title":"Immunoregulation of the in vitro anti\u2010HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti\u2010hepatitis B vaccine recipients","volume":"60","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"hep32314-bib-0085-20250824","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","year":"2018","journal-title":"J Clin Invest"},{"key":"hep32314-bib-0086-20250824","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD\u20101 blockade partially recovers dysfunctional virus\u2010specific B cells in chronic hepatitis B infection","volume":"128","year":"2018","journal-title":"J Clin Invest"},{"key":"hep32314-bib-0087-20250824","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.145.10.3442","article-title":"Cellular immune response to hepatitis B virus\u2010encoded antigens in acute and chronic hepatitis B virus infection","volume":"145","year":"1990","journal-title":"J Immunol"},{"key":"hep32314-bib-0088-20250824","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex vivo analysis of hepatitis B virus\u2010specific CD8+ T cells associated with the control of infection","volume":"117","year":"1999","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0089-20250824","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)\u2010specific T\u2010cell dysfunction in chronic HBV infection","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"hep32314-bib-0090-20250824","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core\u2010specific versus HBV polymerase\u2010specific CD8+ T cells in chronically HBV\u2010infected patients with low viral load","volume":"68","year":"2019","journal-title":"Gut"},{"key":"hep32314-bib-0091-20250824","first-page":"893","article-title":"Phenotype and function of HBV\u2010specific T cells is determined by the targeted epitope in addition to the stage of infection","volume":"68","year":"2018","journal-title":"Gut"},{"key":"hep32314-bib-0092-20250824","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV\u2010specific CD8 T cells in chronic hepatitis B","volume":"23","year":"2017","journal-title":"Nat Med"},{"key":"hep32314-bib-0093-20250824","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.celrep.2016.06.078","article-title":"Distinct metabolic requirements of exhausted and functional virus\u2010specific CD8 T cells in the same host","volume":"16","year":"2016","journal-title":"Cell Rep"},{"key":"hep32314-bib-0094-20250824","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1128\/JVI.00867-09","article-title":"The size of the viral inoculum contributes to the outcome of hepatitis B virus infection","volume":"83","year":"2009","journal-title":"J Virol"},{"key":"hep32314-bib-0095-20250824","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","year":"2003","journal-title":"J Virol"},{"key":"hep32314-bib-0096-20250824","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1084\/jem.178.5.1541","article-title":"Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis","volume":"178","year":"1993","journal-title":"J Exp Med"},{"key":"hep32314-bib-0097-20250824","doi-asserted-by":"crossref","first-page":"13717","DOI":"10.1073\/pnas.172521999","article-title":"Depletion of neutrophils blocks the recruitment of antigen\u2010nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus\u2010specific cytotoxic T lymphocytes","volume":"99","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep32314-bib-0098-20250824","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1317","article-title":"Platelets mediate cytotoxic T lymphocyte\u2013induced liver damage","volume":"11","year":"2005","journal-title":"Nat Med"},{"key":"hep32314-bib-0099-20250824","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.194.12.1755","article-title":"Blocking chemokine responsive to gamma\u20102\/interferon (IFN)\u2010gamma inducible protein and monokine induced by IFN\u2010gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus\u2010specific cytotoxic T lymphocytes","volume":"194","year":"2001","journal-title":"J Exp Med"},{"key":"hep32314-bib-0100-20250824","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1128\/JVI.79.11.7269-7272.2005","article-title":"Toll\u2010like receptor signaling inhibits hepatitis B virus replication in vivo","volume":"79","year":"2005","journal-title":"J Virol"},{"key":"hep32314-bib-0101-20250824","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS\u20109620, an oral agonist of Toll\u2010like receptor\u20107, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0102-20250824","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll\u2010like receptor 8 agonist GS\u20109688 induces sustained efficacy in the woodchuck model of chronic hepatitis B","volume":"73","year":"2021","journal-title":"Hepatology"},{"key":"hep32314-bib-0103-20250824","article-title":"Antiviral efficacy and host immune response induction during sequential treatment with SB 9200 followed by entecavir in woodchucks","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"hep32314-bib-0104-20250824","article-title":"AIC649 induces a bi\u2010phasic treatment response in the woodchuck model of chronic hepatitis B","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep32314-bib-0105-20250824","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/JVI.76.6.2617-2621.2002","article-title":"Interferon\u2010regulated pathways that control hepatitis B virus replication in transgenic mice","volume":"76","year":"2002","journal-title":"J Virol"},{"key":"hep32314-bib-0106-20250824","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/JVI.74.9.4165-4173.2000","article-title":"Intrahepatic induction of alpha\/beta interferon eliminates viral RNA\u2010containing capsids in hepatitis B virus transgenic mice","volume":"74","year":"2000","journal-title":"J Virol"},{"key":"hep32314-bib-0107-20250824","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN\u2010\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","year":"2012","journal-title":"J Clin Invest"},{"key":"hep32314-bib-0108-20250824","article-title":"The third signal cytokine IL\u201012 rescues the anti\u2010viral function of exhausted HBV\u2010specific CD8 T cells","volume":"9","year":"2013","journal-title":"PLoS Pathog"},{"key":"hep32314-bib-0109-20250824","article-title":"Toll\u2010like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","year":"2014","journal-title":"PLoS Pathog"},{"key":"hep32314-bib-0110-20250824","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","year":"1996","journal-title":"Immunity"},{"key":"hep32314-bib-0111-20250824","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4049\/jimmunol.0902761","article-title":"CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions","volume":"184","year":"2010","journal-title":"J Immunol"},{"key":"hep32314-bib-0112-20250824","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon\u2010\u03b3 and tumor necrosis factor\u2010\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0113-20250824","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS\u20109620) in virally suppressed patients with chronic hepatitis B","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep32314-bib-0114-20250824","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS\u20109688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"hep32314-bib-0115-20250824","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus\u2010specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues","volume":"154","year":"2018","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0116-20250824","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.immuni.2014.05.003","article-title":"Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1","volume":"40","year":"2014","journal-title":"Immunity"},{"key":"hep32314-bib-0117-20250824","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/JVI.02415-06","article-title":"The level of viral antigen presented by hepatocytes influences CD8 T\u2010cell function","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"hep32314-bib-0118-20250824","article-title":"Immunomodulation and RNA interference alter hepatitis B virus\u2010specific CD8 T cell recognition of infected HepG2\u2010NTCP","year":"2021","journal-title":"Hepatology"},{"key":"hep32314-bib-0119-20250824","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ni.2573","article-title":"Intrahepatic myeloid\u2010cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection","volume":"14","year":"2013","journal-title":"Nat Immunol"},{"key":"hep32314-bib-0120-20250824","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000489966","article-title":"Characterization of pattern recognition receptor expression and functionality in liver primary cells and derived cell lines","volume":"10","year":"2018","journal-title":"J Innate Immun"},{"key":"hep32314-bib-0121-20250824","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll\u2010like receptor 7 agonist GS\u20109620 in the Woodchuck model of chronic hepatitis B","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep32314-bib-0122-20250824","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bpg.2017.05.004","article-title":"New treatments to reach functional cure: rationale and challenges for emerging immune\u2010based therapies","volume":"31","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"hep32314-bib-0123-20250824","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV\u2010specific T cells after long\u2010term effective therapy with nucleos(t)ide analogues","volume":"143","year":"2012","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0124-20250824","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti\u2010viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","year":"2003","journal-title":"J Hepatol"},{"key":"hep32314-bib-0125-20250824","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/erv.13.15","article-title":"Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials","volume":"12","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"hep32314-bib-0126-20250824","first-page":"261ra153","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV\u2010specific T cell memory","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"hep32314-bib-0127-20250824","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"hep32314-bib-0128-20250824","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1038\/s41598-019-47149-w","article-title":"Synergy of therapeutic heterologous prime\u2010boost hepatitis B vaccination with CpG\u2010application to improve immune control of persistent HBV infection","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"hep32314-bib-0129-20250824","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.gt.3302751","article-title":"Correlation of antiviral T\u2010cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof\u2010of\u2010concept study","volume":"13","year":"2006","journal-title":"Gene Ther"},{"key":"hep32314-bib-0130-20250824","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS\u20104774 and tenofovir therapy can improve HBV\u2010specific T\u2010cell responses in patients with chronic hepatitis","volume":"157","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0131-20250824","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.jhepr.2021.100361","article-title":"Therapeutic vaccine BRII\u2010179 restores HBV\u2010specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","year":"2021","journal-title":"JHEP Rep"},{"key":"hep32314-bib-0132-20250824","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus\u2010specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","year":"2020","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0133-20250824","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T\u2010cell responses can be restored by blocking programmed death\u20101 pathway in chronic hepatitis B","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"key":"hep32314-bib-0134-20250824","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV\u2010specific CD8+ T cell function by PD\u20101 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep32314-bib-0135-20250824","doi-asserted-by":"crossref","first-page":"14113","DOI":"10.1073\/pnas.1903520116","article-title":"Epigenetic signature of PD\u20101+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD\u20101 blockade","volume":"116","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep32314-bib-0136-20250824","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41590-020-00817-w","article-title":"Memory\u2010like HCV\u2010specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection","volume":"22","year":"2021","journal-title":"Nat Immunol"},{"key":"hep32314-bib-0137-20250824","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.2606","article-title":"T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion","volume":"14","year":"2013","journal-title":"Nat Immunol"},{"key":"hep32314-bib-0138-20250824","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti\u2010PD\u20101 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","year":"2019","journal-title":"J Hepatol"},{"key":"hep32314-bib-0139-20250824","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41467-021-21410-1","article-title":"Checkpoint inhibition through small molecule\u2010induced internalization of programmed death\u2010ligand 1","volume":"12","year":"2021","journal-title":"Nat Commun"},{"key":"hep32314-bib-0140-20250824","article-title":"Enhancing virus\u2010specific immunity in vivo by combining therapeutic vaccination and PD\u2010L1 blockade in chronic hepadnaviral infection","volume":"10","year":"2014","journal-title":"PLoS Pathog"},{"key":"hep32314-bib-0141-20250824","first-page":"648420","article-title":"Functional exhaustion of HBV\u2010specific CD8 T cells impedes PD\u2010L1 blockade efficacy in chronic HBV","volume":"12","year":"2021","journal-title":"Infection"},{"key":"hep32314-bib-0142-20250824","article-title":"Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection","volume":"217","year":"2020","journal-title":"J Exp Med"},{"key":"hep32314-bib-0143-20250824","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.4049\/jimmunol.1502061","article-title":"Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination","volume":"196","year":"2016","journal-title":"J Immunol"},{"key":"hep32314-bib-0144-20250824","doi-asserted-by":"crossref","first-page":"485\u2013","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc\u2010optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","year":"2020","journal-title":"Nature"},{"key":"hep32314-bib-0145-20250824","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg\u2010HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep32314-bib-0146-20250824","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.30474","article-title":"The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"hep32314-bib-0147-20250824","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral Toll\u2010like receptor\u20107 agonist GS\u20109620 in patients with chronic hepatitis B virus infection","volume":"63","year":"2015","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32314","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:01:43Z","timestamp":1756076503000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":146,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32314","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"2021-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}